Evidence map›Paper›PMID 40970120›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Similarities and Differences in the Late-Onset GM2 Gangliosidoses: Tay-Sachs and Sandhoff Diseases.

Connor J Lewis, Leila Shirvan, Jean M Johnston, Catherine Groden, John Yang, Andrea Ashton, Jessica Chong, Mark Moran, Hera Akmal, Selby I Chipman and 8 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Connor J LewisOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.ORCID 0000-0002-8204-5848
Leila ShirvanMedical Genetics Branch, National Human Genome Research Institute, Bethesda MD 20892 USA.
Jean M JohnstonOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
Catherine GrodenOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
John YangMedical Genetics Branch, National Human Genome Research Institute, Bethesda MD 20892 USA.
Andrea AshtonOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
Jessica ChongOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
Mark MoranOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
Hera AkmalOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
Selby I ChipmanOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.
Cris ZampieriNeurorehabilitation and Biomechanics Research Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Jordan WickstromNeurorehabilitation and Biomechanics Research Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Jesse MatsubaraNeurorehabilitation and Biomechanics Research Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Frances GavelliNeurorehabilitation and Biomechanics Research Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0002-4110-0468
Tanya LehkyElectromyography Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Katharine E AlterNeurorehabilitation and Biomechanics Research Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0002-5405-2143
Camilo ToroOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.ORCID 0000-0002-3917-9031
Cynthia J TifftOffice of the Clinical Director, National Human Genome Research Institute, Bethesda MD 20892 USA.ORCID 0000-0002-3931-1207

Funding

Pathogenesis informs therapy in the GM1 and GM2 GangliosidosesZIAHG200409 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI TIFFT, CYNTHIA · 2020 to 2025
$4.1M
LONKAGE ANALYSIS OF PROSTATE CANCERZ01HG000107 · NHGRI · HUMAN GENOME RESEARCH · PI BAILEY-WILSON, JOAN E. · 1997 to 2004
–
Intramural NIH HHS Z01 HG000107Intramural NIH HHS ZIA HG200409
6 · The paper itself

Abstract

The two predominating subtypes of late-onset GM2 gangliosidosis are late-onset Tay-Sachs (LOTS) and late-onset Sandhoff disease (LOSD). Due to shared deficiencies of ß-hexosamindase A and significant clinical overlap, the two diseases have been considered indistinguishable. However, a growing body of evidence supports the notion of several distinctions between the two diseases. In this study, we highlight these distinctions through the cross-sectional evaluation of 27 late-onset GM2 gangliosidosis participants. Twenty-one participants with LOTS and 6 with LOSD were included in this study. We performed physical examinations alongside assessments for gait, balance, muscle strength, ataxia, nerve conduction velocities, and analyzed brain magnetic resonance imaging. Lower limb weakness (95% in LOTS, 100% in LOSD) and later development of upper limb weakness (90% in LOTS, 83% in LOSD) was highly prevalent in both cohorts. Accompanying gait disturbances, balance issues, and dysmetria (as assessed by the brief ataxia rating scale [BARS]) were also prevalent in both cohorts. Strength testing for the quadriceps and hamstrings demonstrated weakness in both cohorts, primarily impacting extensor muscles. Supratentorial gray and white matter volumes in both cohorts were similar to normative data. In contrast, BARS scores for dysarthria and oculomotor dysfunction were present and heterogenous in LOTS participants and absent in LOSD participants. 24% of LOTS participants and none of the LOSD participants had a history of neuropsychiatric symptoms. Cerebellar volume including lobules V and VI were lower in LOTS compared to LOSD and normative data. However, length dependent sensory neuropathy was present in all LOSD participants but absent in LOTS participants. Dysfunction of the posterior cerebellum (lobules VI, VII, and IX) has been shown to cause cerebellar cognitive affective syndrome (CCAS), that includes cognitive and behavioral disturbances. Furthermore, cerebellar dysfunction of lobules V and VI has been linked to dysarthric speech, and dysfunction of the posterior cerebellum has been linked to oculomotor symptoms. The finding of low cerebellar lobule volumes in LOTS, suggests the distinctive features of the LOTS phenotype are related to cerebellar dysfunction. However, the sensory symptoms unique to LOSD remains a mystery. The molecular and biochemical basis for the dichotomy between the LOTS and LOSD phenotypes requires further investigation.

Indexed as

GM2 Gangliosidosislysosomal storage diseaseSandhoffTay-Sachs

Identifiers

PMID40970120
PMCPMC12443050

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.